Literature DB >> 3563426

Case fatality of meningococcal disease in western Norway.

A Halstensen, S H Pedersen, B Haneberg, B Bjorvatn, C O Solberg.   

Abstract

In the period 1976-84, 211 patients hospitalized with meningococcal disease were examined for possible relation between various epidemiological parameters and fatality. The peak incidences were in the age groups 0-4 and 13-18 years, with teenage girls peaking 2 years ahead of the boys. The overall case fatality rate was 8.5%. In septicemic patients (without meningitis) hypotension and/or ecchymoses on admission correlated strongly with a poor prognosis. Most deaths occurred during the months of March and November, and none during the summer months. There was a significant clustering of deaths among patients admitted during the morning hours, probably due to delayed diagnosis and treatment during the night. Since almost all patients who died had skin bleedings on admission, frequent examination of the skin in cases with acute unexplained fever might have saved lives.

Entities:  

Mesh:

Year:  1987        PMID: 3563426     DOI: 10.3109/00365548709032375

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  13 in total

1.  Cloning and characterization of a DNA fragment that confers sulfonamide resistance in a serogroup B, serotype 15 strain of Neisseria meningitidis.

Authors:  B E Kristiansen; P Rådström; A Jenkins; E Ask; B Facinelli; O Sköld
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review.

Authors:  Susan J M Hahné; André Charlett; Bernadette Purcell; Susanne Samuelsson; Ivonne Camaroni; Ingrid Ehrhard; Sigrid Heuberger; Maria Santamaria; James M Stuart
Journal:  BMJ       Date:  2006-06-03

Review 3.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985-2002.

Authors:  I Smith; A T Bjørnevik; I M B Augland; A Berstad; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

5.  A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course.

Authors:  M Van Deuren; C Neeleman; L G Van 't Hek; J W Van der Meer
Journal:  Intensive Care Med       Date:  1998-02       Impact factor: 17.440

6.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

7.  Rapid diagnosis of acute meningococcal infections by needle aspiration or biopsy of skin lesions.

Authors:  M van Deuren; B J van Dijke; R J Koopman; A M Horrevorts; J F Meis; F W Santman; J W van der Meer
Journal:  BMJ       Date:  1993-05-08

8.  Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003-2005.

Authors:  S C de Greeff; H E de Melker; L M Schouls; L Spanjaard; M van Deuren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-21       Impact factor: 3.267

9.  Targeted vaccination with meningococcal polysaccharide vaccine in one district of the Czech Republic.

Authors:  P Kriz; J Vlckova; M Bobak
Journal:  Epidemiol Infect       Date:  1995-12       Impact factor: 2.451

10.  Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis.

Authors:  R J Scholten; H A Bijlmer; H A Valkenburg; J Dankert
Journal:  Epidemiol Infect       Date:  1994-02       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.